Millennium kept by JMP at market perform

Millennium Pharmaceuticals Inc. was maintained by JMP Securities analyst Charles Duncan at a market perform rating on its sale of the U.S. licensing of Integrilin to Schering Plough Corp. for an upfront payment of $35.5 million plus future royalty payments of $85 million in 2006 and 2007, in addition to a $45 million to $50 million payment for current inventory. Millennium shares Monday dipped $0.09, or 0.91%, to close at $9.84 on volume of 11,580,803 shares versus the three-month running average of 7,003,720 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.